×
About 3,445 results

ALLMedicine™ Acromegaly Center

Research & Reviews  1,190 results

Pasireotide-a novel somatostatin receptor ligand after 20 years of use.
https://doi.org/10.1007/s11154-022-09710-3 10.1126/science.179.4068.77 10.1210/edrv-16-4-427 10.1056/NEJM198312223092506 10.3390/ijms21051682 10.1016/j.tem.2009.12.003 10.1530/eje.0.1460707 10.1210/jc.2008-1919 10.1006/frne.1999.0183 10.1016/0024-3205(82)90087-x 10.1056/NEJM198512193132504 10.1210/jcem.79.1.8027218 10.1007/s11154-020-09588-z 10.1007/s11102-020-01091-7 10.1210/jcem.80.11.7593436 10.1210/jcem.87.1.8153 10.1007/s11102-017-0791-0 10.1007/s11102-015-0684-z 10.1210/jc.2013-3318 10.1210/jc.2014-4113 10.1210/clinem/dgaa526 10.1210/jc.2013-2262 10.1210/jc.2013-2480 10.1016/S2213-8587(17)30326-1 10.3389/fendo.2018.00358 10.1007/s11102-014-0585-6 10.1210/jc.2013-1771 10.3389/fendo.2020.00028 10.1038/s41574-018-0058-5 10.1210/jc.2018-01979 10.1530/ERC-15-0478 10.1210/jc.2003-031052 10.1210/jc.2009-2272 10.1186/s12902-016-0096-8 10.1210/jc.2017-00135 10.1530/JOE-16-0332 10.1016/S2213-8587(14)70169-X 10.1530/EJE-19-0762 10.1210/jc.2017-02017 10.1530/EJE-18-0353 10.1007/s12020-018-1690-5 10.1530/EC-19-0332 10.3389/fendo.2021.633944 10.1016/S2213-8587(19)30113-5 10.1530/EJE-19-0840 10.1530/EJE-15-0832 10.3389/fendo.2021.648411 10.1530/EJE-20-0767 10.1046/j.1365-2265.2000.00986.x 10.1007/s11102-016-0734-1 10.1530/EC-20-0361 10.1007/s12020-016-1182-4 10.1056/NEJMoa1105743 10.1007/s11102-013-0483-3 10.2174/1871530320666200129113328 10.1007/s11102-013-0478-0 10.1007/BF03346419 10.1210/er.2013-1048 10.1007/s11102-018-0926-y 10.1159/000314296 10.1007/s11102-014-0618-1 10.1111/cen.12431 10.1007/s12020-018-1524-5 10.1007/s12020-018-1818-7 10.1007/s12020-015-0557-2 10.1007/s11102-017-0853-3 10.1677/ERC-06-0026 10.1038/ng.3166 10.1038/cr.2015.20 10.1007/s11102-019-01021-2 10.1530/EJE-15-0689 10.5114/fn.2020.102438 10.1530/EJE-13-0754 10.3389/fendo.2020.00648 10.1530/EJE-19-0695 10.1016/S2213-8587(17)30341-8 10.1056/NEJMc1000094 10.1056/NEJMoa1316158 10.1200/JCO.2009.22.8510 10.2147/DDDT.S84177 10.1530/ERC-11-0367 10.1007/s12020-020-02406-1 10.1111/cen.13503 10.1007/s12020-018-1583-7 10.2147/JHC.S153672 10.1016/j.urolonc.2020.07.005 10.1210/jcem.80.9.7673428 10.2147/CPAA.S278978 10.1007/s11695-019-04248-x 10.1007/s00592-021-01723-9 10.6065/apem.2142010.005 10.1177/0003134820947371 10.1186/s40842-020-00110-7 10.1016/j.ando.2018.07.013 10.2215/CJN.13661119
Reviews in Endocrine & Metabolic Disorders; Bolanowski M, Kałużny M et. al.

Jan 25th, 2022 - Pasireotide, a novel multireceptor-targeted somatostatin receptor ligand (SRL) is characterized by a higher affinity to somatostatin receptor type 5 than type 2, unlike first-generation SRLs. Because of the broader binding profile, pasireotide has...

Petrified ears due to auricular ossification: an underreported clinical sign in acromeg...
https://doi.org/10.1136/bcr-2021-247186
BMJ Case Reports; Awasthi A, Agrawal N et. al.

Jan 19th, 2022 - Petrified ears due to auricular ossification: an underreported clinical sign in acromegaly.|2022|Awasthi A,Agrawal N,Chakraborty PP,Maiti A,|

Virtual education programming for patients with acromegaly: a pilot study.
https://doi.org/10.1530/EJE-21-1071
European Journal of Endocrinology; Geer EB, Kilgallon JL et. al.

Jan 16th, 2022 - To assess the impact of virtual education programming for patients with acromegaly. We conducted a mixed methods study to evaluate patient attitudes, examine if patient-centered educational forums change these attitudes, and determine the role of ...

Personalized Medical Treatment in Patients with Acromegaly: A Review.
https://doi.org/10.1016/j.eprac.2021.12.017
Endocrine Practice : Official Journal of the American Col... Ting Lim DS, Fleseriu M

Jan 16th, 2022 - Acromegaly is associated with significant morbidity and mortality if not appropriately treated. In addition to insulin-like growth factor 1 (IGF-1) and growth hormone (GH) normalization, and tumor shrinkage, treatment goals include symptom relief,...

Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the A...
https://doi.org/10.1007/s11102-022-01206-2
Pituitary Salvatori R, Maffei P et. al.

Jan 14th, 2022 - To report the effects of pegvisomant (PEGV) treatment on patient-reported outcomes in acromegaly patients. We conducted an extension study of an open-label, multinational, non-interventional study (ACROSTUDY) evaluating the long-term safety and ef...

see more →

Guidelines  5 results

Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) ...
https://doi.org/10.1016/j.numecd.2016.02.001
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD; Baroni MG, Giorgino F et. al.

Feb 26th, 2016 - Hyperglycemia is a common feature associated with states of increased growth hormone secretion and glucocorticoid levels. The purpose of these guidelines is to assist clinicians and other health care providers to take evidence-based therapeutic de...

Expert consensus document: A consensus on the medical treatment of acromegaly.
https://doi.org/10.1038/nrendo.2014.21
Nature Reviews. Endocrinology; Giustina A, Chanson P et. al.

Feb 26th, 2014 - In March 2013, the Acromegaly Consensus Group met to revise and update guidelines for the medical treatment of acromegaly. The meeting comprised experts skilled in the medical management of acromegaly. The group considered treatment goals covering...

American Association of Clinical Endocrinologists medical guidelines for clinical pract...
https://www.ncbi.nlm.nih.gov/pubmed/21846616
Endocrine Practice : Official Journal of the American Col... Katznelson L, Atkinson JL et. al.

Aug 24th, 2011 - American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update.|2011|Katznelson L,Atkinson JL,Cook DM,Ezzat SZ,Hamrahian AH,|diagnosis,therapy,standards,trends,...

AME Position Statement on clinical management of acromegaly.
https://www.ncbi.nlm.nih.gov/pubmed/19923883
Journal of Endocrinological Investigation; Cozzi R, Baldelli R et. al.

Jan 23rd, 2010 - AME Position Statement on clinical management of acromegaly.|2010|Cozzi R,Baldelli R,Colao A,Lasio G,Zini M,|diagnosis,economics,epidemiology,therapy,

Guidelines for acromegaly management: an update.
https://doi.org/10.1210/jc.2008-2421
The Journal of Clinical Endocrinology and Metabolism; Melmed S, Colao A et. al.

Feb 12th, 2009 - The Acromegaly Consensus Group reconvened in November 2007 to update guidelines for acromegaly management. The meeting participants comprised 68 pituitary specialists, including neurosurgeons and endocrinologists with extensive experience treating...

see more →

Drugs  26 results see all →

Clinicaltrials.gov  61 results

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
https://clinicaltrials.gov/ct2/show/NCT05192382

Jan 14th, 2022 - A randomized, placebo-controlled study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with non-pharmacologically treated acromeg...

Patient and Physician Survey on Satisfaction With Somatostatin Analogue (SSA) Injections in Acromegaly in China
https://clinicaltrials.gov/ct2/show/NCT05184231

Jan 11th, 2022 - The purpose of the protocol is to achieve an in-depth understanding of the current satisfaction status of somatostatin analogue (SSA) treatment for acromegaly through patient and physician surveys.

Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess
https://clinicaltrials.gov/ct2/show/NCT03882034

Dec 28th, 2021 - Growth hormone excess is a rare and potentially lethal condition associated with hypersecretion of growth hormone (GH), usually by a pituitary tumor or hyperplasia. When it occurs prior to the complete fusion of growth plates, it leads to patholog...

A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
https://clinicaltrials.gov/ct2/show/NCT04125836

Dec 6th, 2021 - The purpose of this trial is to assess the long-term safety of CAM2029 in patients with acromegaly. Patients will be administered CAM2029 subcutaneously once monthly during 12 months. Patients fulfilling trial NCT04076462 will be offered to contin...

Nasal Packing Following Endoscopic Endonasal Pituitary Resection
https://clinicaltrials.gov/ct2/show/NCT03677713

Sep 9th, 2021 - BACKGROUND AND CLINICAL SIGNIFICANCE Over the past decade, the surgical method for removing pituitary tumors has shifted from a microscopic resection technique performed exclusively by a neurosurgeon, to an endoscopic resection done as a team with...

see more →

News  92 results

Oral Octreotide Shows Promise as Alternative to Injections for Acromegaly
https://www.medscape.com/viewarticle/966233

Jan 10th, 2022 - NEW YORK (Reuters Health) - Many patients with acromegaly may do as well on oral octreotide treatment as they do on injectable somatostatin receptor ligands (iSRLs), an industry-sponsored phase-3 trial suggests. Oral octreotide is the first oral m...

Association of Circulating IGF-I with Common Non-cancerous Conditions
https://www.medscape.com/viewarticle/963018

Nov 15th, 2021 - Takeaway Circulating insulin-like growth factor-I (IGF-I) was associated with several common conditions (other than cancer), including a positive association with carpal tunnel syndrome and inverse associations with varicose veins and iron deficie...

FDA Approvals in Myeloma, NETs, and of a Biosimilar, Priority Review in Ovarian Cancer, and More
https://www.onclive.com/view/fda-approvals-in-myeloma-nets-and-of-a-biosimilar-priority-review-in-ovarian-cancer-and-more

Apr 2nd, 2021 - Today- FDA approvals in multiple myeloma, neuroendocrine tumors, and of a biosimilar, a priority review designation in ovarian cancer, a partial clinical hold lifted in multiple myeloma, and encouraging findings in a lung cancer trial. Welco...

FDA Approves Lanreotide for Gastroenteropancreatic Neuroendocrine Tumors
https://www.onclive.com/view/fda-approves-lanreotide-for-gastroenteropancreatic-neuroendocrine-tumors

Dec 4th, 2020 - Alexandria Phan, MD The FDA has approved lanreotide (Somatuline Depot Injection) for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-...

FDA Grants Priority Review to Lanreotide for GEP NETs
https://www.onclive.com/view/fda-grants-priority-review-to-lanreotide-for-gep-nets

Dec 4th, 2020 - Marc de Garidel The FDA has assigned a priority review designation to lanreotide (Somatuline Depot) as a treatment for patients with gastroenteropancreatic (GEP) neuroendocrine tumors (NETs), based on findings from the phase III CLARINET study. ...

see more →

Patient Education  4 results see all →